[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mineralys Therapeutics Inc (MLYS)

Mineralys Therapeutics Inc (MLYS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,598,687
  • Shares Outstanding, K 82,498
  • Annual Sales, $ 0 K
  • Annual Income, $ -154,650 K
  • EBIT $ -172 M
  • EBITDA $ -171 M
  • 60-Month Beta 0.49
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.08

Options Overview Details

View History
  • Implied Volatility 78.01% (+2.11%)
  • Historical Volatility 59.42%
  • IV Percentile 22%
  • IV Rank 25.52%
  • IV High 145.27% on 03/05/26
  • IV Low 54.96% on 09/24/25
  • Expected Move (DTE 16) 4.04 (12.98%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 264
  • Volume Avg (30-Day) 936
  • Put/Call OI Ratio 0.56
  • Today's Open Interest 23,351
  • Open Int (30-Day) 24,981
  • Expected Range 27.07 to 35.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.54
  • Number of Estimates 4
  • High Estimate $-0.45
  • Low Estimate $-0.61
  • Prior Year $-0.66
  • Growth Rate Est. (year over year) +18.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.64 +21.33%
on 05/19/26
32.14 -3.20%
on 05/29/26
+1.85 (+6.32%)
since 05/01/26
3-Month
22.42 +38.76%
on 03/24/26
32.14 -3.20%
on 05/29/26
+1.85 (+6.32%)
since 02/27/26
52-Week
12.59 +147.10%
on 08/13/25
47.65 -34.71%
on 11/12/25
+15.53 (+99.68%)
since 05/30/25

Most Recent Stories

More News
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants with chronic kidney disease – – In participants...

MLYS : 31.11 (-1.24%)
Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference

RADNOR, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities...

MLYS : 31.11 (-1.24%)
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

– Oral presentation highlights efficacy and safety profile of lorundrostat in patients with uncontrolled hypertension and chronic kidney disease – RADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) --...

MLYS : 31.11 (-1.24%)
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

– NDA for lorundrostat in adults with hypertension accepted by FDA; assigned PDUFA target date of December 22, 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., May 06,...

MLYS : 31.11 (-1.24%)
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities...

MLYS : 31.11 (-1.24%)
Mineralys Therapeutics Reports First Quarter Results With Lorundrostat Trial Data Still Pending

Barchart Research What to Expect from MLYS Earnings MLYS Generated May 5, 2026 Current Price $29.28 EPS Estimate $$-0.51 Consensus Rating Strong Buy Average Move 6.61% Mineralys Therapeutics Reports First...

MLYS : 31.11 (-1.24%)
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

RADNOR, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities...

MLYS : 31.11 (-1.24%)
Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026

RADNOR, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities...

MLYS : 31.11 (-1.24%)
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer

RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities...

MLYS : 31.11 (-1.24%)
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities...

MLYS : 31.11 (-1.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Mineralys Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Mineralys Therapeutics Inc. is based in RADNOR, Pa.

See More

Key Turning Points

3rd Resistance Point 33.93
2nd Resistance Point 32.92
1st Resistance Point 32.02
Last Price 31.11
1st Support Level 30.11
2nd Support Level 29.10
3rd Support Level 28.20

See More

52-Week High 47.65
Fibonacci 61.8% 34.26
Last Price 31.11
Fibonacci 50% 30.12
Fibonacci 38.2% 25.98
52-Week Low 12.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.